Gro Leite Størvold
Gro Leite Størvold has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Guro Mørk Johnsen
Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Norway; Division of Obstetrics and Gyneacology, Oslo University Hospital, Norway; Institute for Experimental Medical Research, Oslo University Hospital, Norway
5 shared publications Anne Cathrine Staff
Department of Obstetrics and Gynecology, Oslo University Hospital, Ullevål, Norway; Faculty of Medicine, University of Oslo, Norway
3 shared publicationsPatji Alnæs-Katjavivi
Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Norway; Division of Obstetrics and Gyneacology, Oslo University Hospital, Norway
3 shared publicationsAnne Catherine Staff
2 shared publicationsChristopher W. Redman
2 shared publications- Eirik Frengen
Department of Medical Genetics, Oslo University Hospital and University of Oslo, Oslo, Norway
2 shared publications
Latest Publications
- Open Access
- 1 January 2025
- Published by Wiley in Emergency Medicine International
- Vol. 2025 (1) , 5717892
Analytical and Clinical Performance of High‐Sensitivity Cardiac Troponin Point‐of‐Care Assays as an Aid in the Diagnosis of Myocardial Infarction: A Narrative Review
Background: Acute coronary syndrome (ACS) poses a significant burden worldwide; however, the development of high‐sensitivity cardiac troponin (hs‐cTn) assays has greatly improved patient management by enabling the detection of very low levels of troponin. The objective of this review was to identify current hs‐cTn point‐of‐care (POC) assays, describe their key features, and discuss their analytical and clinical performance. Methods: PubMed, MEDLINE, and Embase databases, as well as relevant web sources, were searched for publications up to April 10, 2025. The references included describe the main characteristics of POC hs‐cTn assays and their companion instruments, as well as studies assessing their analytical or clinical performance in the context of acute myocardial infarction diagnosis. Results: In addition to information publicly available from the web, 27 publications were considered relevant for this review. From the retrieved sources, seven POC hs‐cTn assays were identified as currently cleared by the United States Food and Drug Administration or CE‐marked. Four additional POC hs‐cTn assays, each evaluated for analytical or clinical performance, were identified as currently or previously under development. POC instruments differ in their key characteristics, many of which are crucial for ensuring their suitability in specific clinical settings and intended applications. Despite some variability in performance across different platforms, they are generally consistent with the high‐sensitivity profile expected of cTn assays. Clinical performance indicators for hs‐cTn assays align with European Society of Cardiology (ESC) recommendations, particularly when ESC‐recommended diagnostic algorithms are applied. Reported sensitivity and negative predictive values exceed 99%, while positive predictive values are above 70%. Moreover, comparative studies of POC hs‐cTn assays and laboratory‐based hs‐cTn tests have demonstrated no significant differences in diagnostic accuracy for ruling in or ruling out acute myocardial infarction. Conclusion: POC hs‐cTn assays represent a promising alternative to traditional laboratory testing, providing similar analytical and clinical performance while enabling faster diagnosis and management of ACS. Expanded use of hs‐cTn assays in clinical practice could transform patient care pathways, especially in time‐critical situations. Continued research and ongoing technological advancements are critical to ensure optimal use and widespread adoption in routine clinical settings.
- 1 January 2025
- Published by Wiley in Emergency Medicine International
- Vol. 2025 (1) , 5717892
Open AccessAnalytical and Clinical Performance of High‐Sensitivity Cardiac Troponin Point‐of‐Care Assays as an Aid in the Diagnosis of Myocardial Infarction: A Narrative Review
Background: Acute coronary syndrome (ACS) poses a significant burden worldwide; however, the development of high‐sensitivity cardiac troponin (hs‐cTn) assays has greatly improved patient management by enabling the detection of very low levels of troponin. The objective of this review was to identify current hs‐cTn point‐of‐care (POC) assays, describe their key features, and discuss their analytical and clinical performance. Methods: PubMed, MEDLINE, and Embase databases, as well as relevant web sources, were searched for publications up to April 10, 2025. The references included describe the main characteristics of POC hs‐cTn assays and their companion instruments, as well as studies assessing their analytical or clinical performance in the context of acute myocardial infarction diagnosis. Results: In addition to information publicly available from the web, 27 publications were considered relevant for this review. From the retrieved sources, seven POC hs‐cTn assays were identified as currently cleared by the United States Food and Drug Administration or CE‐marked. Four additional POC hs‐cTn assays, each evaluated for analytical or clinical performance, were identified as currently or previously under development. POC instruments differ in their key characteristics, many of which are crucial for ensuring their suitability in specific clinical settings and intended applications. Despite some variability in performance across different platforms, they are generally consistent with the high‐sensitivity profile expected of cTn assays. Clinical performance indicators for hs‐cTn assays align with European Society of Cardiology (ESC) recommendations, particularly when ESC‐recommended diagnostic algorithms are applied. Reported sensitivity and negative predictive values exceed 99%, while positive predictive values are above 70%. Moreover, comparative studies of POC hs‐cTn assays and laboratory‐based hs‐cTn tests have demonstrated no significant differences in diagnostic accuracy for ruling in or ruling out acute myocardial infarction. Conclusion: POC hs‐cTn assays represent a promising alternative to traditional laboratory testing, providing similar analytical and clinical performance while enabling faster diagnosis and management of ACS. Expanded use of hs‐cTn assays in clinical practice could transform patient care pathways, especially in time‐critical situations. Continued research and ongoing technological advancements are critical to ensure optimal use and widespread adoption in routine clinical settings.
- Open Access
- 1 April 2019
- Published by Elsevier in Journal of Reproductive Immunology
- Vol. 132, 42-48
Lymphocyte characterization of decidua basalis spiral arteries with acute atherosis in preeclamptic and normotensive pregnancies
- 1 April 2019
- Published by Elsevier in Journal of Reproductive Immunology
- Vol. 132, 42-48
Open AccessLymphocyte characterization of decidua basalis spiral arteries with acute atherosis in preeclamptic and normotensive pregnancies
- 1 September 2018
- Published by Elsevier in Journal of Reproductive Immunology
- Vol. 129, 23-29
The combination of maternal KIR-B and fetal HLA-C2 is associated with decidua basalis acute atherosis in pregnancies with preeclampsia
- 1 September 2018
- Published by Elsevier in Journal of Reproductive Immunology
- Vol. 129, 23-29
The combination of maternal KIR-B and fetal HLA-C2 is associated with decidua basalis acute atherosis in pregnancies with preeclampsia
- Open Access
- 1 April 2018
- Published by Elsevier in Pregnancy Hypertension
- Vol. 12, 144-149
Endoglin pathway genetic variation in preeclampsia: A validation study in Norwegian and Latina cohorts
- 1 April 2018
- Published by Elsevier in Pregnancy Hypertension
- Vol. 12, 144-149
Open AccessEndoglin pathway genetic variation in preeclampsia: A validation study in Norwegian and Latina cohorts
- 1 June 2016
- Published by Elsevier in Journal of Reproductive Immunology
- Vol. 115, 63-64
Maternal KIR-B haplotype in combination with fetal HLA-C2 is associated with pregnancy acute atherosis in the decidua basalis
- 1 June 2016
- Published by Elsevier in Journal of Reproductive Immunology
- Vol. 115, 63-64
Maternal KIR-B haplotype in combination with fetal HLA-C2 is associated with pregnancy acute atherosis in the decidua basalis
- 1 October 2013
- Published by Elsevier in Journal of Proteomics
- Vol. 91, 344-357
Quantitative profiling of tyrosine phosphorylation revealed changes in the activity of the T cell receptor signaling pathway upon cisplatin-induced apoptosis
- 1 October 2013
- Published by Elsevier in Journal of Proteomics
- Vol. 91, 344-357
Quantitative profiling of tyrosine phosphorylation revealed changes in the activity of the T cell receptor signaling pathway upon cisplatin-induced apoptosis
- Open Access
- 16 October 2009
- Published by Springer Nature in BMC Biotechnology
- Vol. 9 (1) , 88
Regulated expression of a transgene introduced on an oriP/EBNA-1 PAC shuttle vector into human cells
Background: Sequencing of the human genome has led to most genes being available in BAC or PAC vectors. However, limited functional information has been assigned to most of these genes. Techniques for the manipulation and transfer of complete functional units on large DNA fragments into human cells are crucial for the analysis of complete genes in their natural genomic context. One limitation of the functional studies using these vectors is the low transfection frequency. Results: We have constructed a shuttle vector, pPAC7, which contains both the EBNA-1 gene and oriP from the Epstein-Barr virus allowing stable maintenance of PAC clones in the nucleus of human cells. The pPAC7 vector also contains the EGFP reporter gene, which allows direct monitoring of the presence of PAC constructs in transfected cells, and the Bsr-cassette that allows highly efficient and rapid selection in mammalian cells by use of blasticidin. Positive selection for recombinant PAC clones is obtained in pPAC7 because the cloning sites are located within the SacBII gene. We show regulated expression of the CDH3 gene carried as a 132 kb genomic insert cloned into pPAC7, demonstrating that the pPAC7 vector can be used for functional studies of genes in their natural genomic context. Furthermore, the results from the transfection of a range of pPAC7 based constructs into two human cell lines suggest that the transfection efficiencies are not only dependent on construct size. Conclusion: The shuttle vector pPAC7 can be used to transfer large genomic constructs into human cells. The genes transferred could potentially contain all long-range regulatory elements, including their endogenous regulatory promoters. Introduction of complete genes in PACs into human cells would potentially allow complementation assays to identify or verify the function of genes affecting cellular phenotypes.
- 16 October 2009
- Published by Springer Nature in BMC Biotechnology
- Vol. 9 (1) , 88
Open AccessRegulated expression of a transgene introduced on an oriP/EBNA-1 PAC shuttle vector into human cells
Background: Sequencing of the human genome has led to most genes being available in BAC or PAC vectors. However, limited functional information has been assigned to most of these genes. Techniques for the manipulation and transfer of complete functional units on large DNA fragments into human cells are crucial for the analysis of complete genes in their natural genomic context. One limitation of the functional studies using these vectors is the low transfection frequency. Results: We have constructed a shuttle vector, pPAC7, which contains both the EBNA-1 gene and oriP from the Epstein-Barr virus allowing stable maintenance of PAC clones in the nucleus of human cells. The pPAC7 vector also contains the EGFP reporter gene, which allows direct monitoring of the presence of PAC constructs in transfected cells, and the Bsr-cassette that allows highly efficient and rapid selection in mammalian cells by use of blasticidin. Positive selection for recombinant PAC clones is obtained in pPAC7 because the cloning sites are located within the SacBII gene. We show regulated expression of the CDH3 gene carried as a 132 kb genomic insert cloned into pPAC7, demonstrating that the pPAC7 vector can be used for functional studies of genes in their natural genomic context. Furthermore, the results from the transfection of a range of pPAC7 based constructs into two human cell lines suggest that the transfection efficiencies are not only dependent on construct size. Conclusion: The shuttle vector pPAC7 can be used to transfer large genomic constructs into human cells. The genes transferred could potentially contain all long-range regulatory elements, including their endogenous regulatory promoters. Introduction of complete genes in PACs into human cells would potentially allow complementation assays to identify or verify the function of genes affecting cellular phenotypes.